Author(s): Carter P
Abstract Share this page
Abstract A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer, many innovative approaches stand poised to improve the efficacy of antibody-based therapies.
This article was published in Nat Rev Cancer
and referenced in Journal of Glycomics & Lipidomics